Anti-TES antibody produced in rabbit

TES (testin) is a tumor suppressor gene, which is localized to human chromosome 7q31.2. It is composed of seven exons, and codes for a protein made of 421 amino acids. It has three zinc-binding domains, present in its three LIM (Lin-11, Isl-1, and Mec-3) domains. This gene spans ~48kb, and produces three isoforms due to alternate splicing. This protein is highly conserved in nature.

Testin recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

TES (testin) is present at cell-cell junctions, along with actin stress fibers, and plays an essential role in the formation of focal adhesions. It suppresses miR-29, and thus, reduces the invasiveness of breast cancer cells. Hypermethylation or loss of heterozygosity leads to its reduction or complete inactivation in sexual hormone related cancers like prostate and breast, ovarian cancer and glioblastoma. It is inactivated in endometrial carcinoma, and might have potential as a therapeutic target or marker for the prognosis of the same. This gene is hypermethylated, and hence suppressed in breast cancer, which is associated with poor prognosis. Activation of TES results in induction of RhoA, which leads to inhibition of epithelial-mesenchymal transition processes.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Corresponding Antigen APREST72805

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.